
    
      The one or two cohorts during the dose expansion phase (Part B) will enroll subjects with
      relapsed or refractory follicular lymphoma (FL) who were either refractory to or relapsed
      after treatment with a lenalidomide-containing regimen (FL-1 cohort) or never been exposed to
      lenalidomide (FL-2 cohort). The FL-1 and FL-2 cohorts will enroll up to 20 and/or up to 30
      subjects, respectively.
    
  